Atria Investments LLC Uni Qure N.V. Transaction History

Atria Investments LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 04, 2022	SELL	$20.24 - $36.01 $668,952 - $1.19 Million	-33,051 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$26.01 - $38.22 $658,755 - $967,997	25,327 Added 327.9%	33,051 $1.06 Million
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $48,972 - $90,539	1,224 Added 18.83%	7,724 $367,000
Q4 2019 Feb 11, 2020	BUY	$37.13 - $74.62 $35,681 - $71,709	961 Added 17.35%	6,500 $466,000
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $28,103 - $54,835	714 Added 14.8%	5,539 $218,000
Q2 2019 Aug 26, 2019	SELL	$52.76 - $82.19 $211,673 - $329,746	-4,012 Reduced 45.4%	4,825 $270,000
Q2 2019 Aug 09, 2019	BUY	$52.76 - $82.19 $8,441 - $13,150	160 Added 1.84%	8,837 $1.13 Million
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $18,543 - $46,313	677 Added 8.46%	8,677 $518,000
Q4 2018 Feb 12, 2019	BUY	$22.8 - $33.93 $182,400 - $271,440	8,000 New	8,000 $231,000
Q3 2018 Oct 09, 2018	SELL	$29.75 - $43.08 $194,505 - $281,657	-6,538 Closed	0 $0
Q2 2018 Jul 13, 2018	BUY	$21.96 - $39.94 $143,574 - $261,127	6,538 New	6,538 $247,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Atria Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Atria Investments LLC with notifications on news.